Patents by Inventor Allen B. Reitz

Allen B. Reitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11358935
    Abstract: Pharmaceutical compositions of the invention include substituted Lanicemine prodrugs useful for the treatment of conditions associated with dysregulation of NMDA receptor activity such as depression and depressive disorders through the release of Lanicemine, Prodrugs of Lanicemine have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release Lanicemine in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: June 14, 2022
    Assignee: Biohaven Pharmaceutical Holding Company Ltd.
    Inventors: Allen B. Reitz, Jeffery Claude Pelletier
  • Patent number: 11306075
    Abstract: Novel benzofurans, benzothiophenes and indoles useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said compounds, processes for the preparation of said compounds, intermediates used in the preparation of said compounds, and pharmaceutical compositions containing said compounds. The invention further relates to methods of use of said compounds, salts of said compounds, and said compositions in treating neurodegenerative diseases and related conditions.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: April 19, 2022
    Assignee: Oligomerix, Inc.
    Inventors: Eliot J. Davidowitz, James G. Moe, Allen B. Reitz, Haiyan Bian, Charles Gluchowski, James Hendrix, Albert S. Yehaskel, Mark E. McDonnell, H. Marie Loughran
  • Publication number: 20220072006
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Allen B. Reitz, Garry Robert Smith
  • Publication number: 20220064112
    Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Application
    Filed: April 16, 2021
    Publication date: March 3, 2022
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen
  • Patent number: 11242317
    Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: February 8, 2022
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Venkata Velvadapu
  • Publication number: 20210395223
    Abstract: Disclosed are prodrugs of CGRP antagonists, methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof the prodrugs, pharmaceutical compositions comprising prodrugs and kits including the pharmaceutical compositions and instructions for use.
    Type: Application
    Filed: October 10, 2019
    Publication date: December 23, 2021
    Inventors: Charles M. Conway, Gene M. Dubowchik, Jeffrey Claude Pelletier, Allen B. Reitz
  • Patent number: 11197864
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1?2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: December 14, 2021
    Assignee: Biohaven Pharmaceutical Holding Company Limited
    Inventors: Allen B. Reitz, Garry Robert Smith
  • Publication number: 20210236470
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: January 18, 2021
    Publication date: August 5, 2021
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Publication number: 20210236471
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 5, 2021
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Publication number: 20210228549
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: January 18, 2021
    Publication date: July 29, 2021
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Patent number: 11052070
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: July 6, 2021
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Publication number: 20210130335
    Abstract: Novel benzofurans, benzothiophenes and indoles useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said compounds, processes for the preparation of said compounds, intermediates used in the preparation of said compounds, and pharmaceutical compositions containing said compounds. The invention further relates to methods of use of said compounds, salts of said compounds, and said compositions in treating neurodegenerative diseases and related conditions.
    Type: Application
    Filed: December 18, 2017
    Publication date: May 6, 2021
    Inventors: Eliot J. Davidowitz, James G. Moe, Allen B. Reitz, Haiyan Bian, Charles Gluchowski, James Hendrix, Albert S. Yehaskel, Mark E. McDonnell, Marie H. Loughran
  • Patent number: 10981867
    Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: April 20, 2021
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen
  • Publication number: 20210078962
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 18, 2021
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Patent number: 10905681
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: February 2, 2021
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jefferey Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Patent number: 10844026
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: November 24, 2020
    Assignees: Biohaven Pharmaceutical Holding Company Ltd., Rutgers, The State University of New Jersey
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Publication number: 20200299238
    Abstract: Pharmaceutical compositions of the invention include substituted Lanicemine prodrugs useful for the treatment of conditions associated with dysregulation of NMDA receptor activity such as depression and depressive disorders through the release of Lanicemine, Prodrugs of Lanicemine have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release Lanicemine in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: November 22, 2017
    Publication date: September 24, 2020
    Inventors: Allen B. Reitz, Jeffery Claude Pelletier
  • Patent number: 10780084
    Abstract: The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: September 22, 2020
    Assignees: YALE UNIVERSITY, KLEO PHARMACEUTICALS, INC.
    Inventors: David Spiegel, H. Marie Loughran, Jeffrey C. Pelletier, Allen B. Reitz, Matthew Ernest Welsch
  • Publication number: 20200289475
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: June 24, 2019
    Publication date: September 17, 2020
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jefferey Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Publication number: 20200239415
    Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Application
    Filed: September 16, 2019
    Publication date: July 30, 2020
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen